FDA approves Merck rotavirus vaccine

Share this article:
The FDA has approved Merck’s RotaTeq (rotavirus vaccine, live, oral, pentavalent) to prevent rotavirus gastroenteritis, a leading cause of severe diarrhea in infants and young children that kills nearly 500,000 children globally each year. Analysts forecast the vaccine could bring Merck as much as $500 million annually by 2009. RotaTeq is the second vaccine for rotavirus to be put on the market. The first, Wyeth’s RotaSheild, was withdrawn just 10 months after it debuted in September 1998.  The drug maker could start fielding orders from doctors immediately and would be able to ship doses as early as this week.
Share this article:
You must be a registered member of MMM to post a comment.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters